/
Other
Untreated Advanced NSCLC
4
Pipeline Programs↗
2
Active Trials↗
4
Companies Involved↗
Untreated Advanced NSCLC is an early-stage landscape with 4 programs across 4 companies. The most active players are Shanghai Henlius Biotech.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 1
No programs
Phase 24
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
75%
Small molecule
3 of 4 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 4 classified programs, each share of the total. Modality classified for 100% of 4 pipeline programs.
Analysis
Trial Status
3
clinical trials
Recruiting1 · 33%
Active, not recruiting1 · 33%
Completed1 · 33%
Clinical Trials
Trial Activity
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)